ASX:TLXBiotechs
Why Telix Pharmaceuticals (ASX:TLX) Is Down 5.9% After Class Action Lawsuits Over Prostate Therapy Disclosures and What's Next
In recent days, several law firms announced the filing of class action lawsuits against Telix Pharmaceuticals, alleging the company made false and misleading statements about its progress developing prostate cancer therapies and the strength of its supply chain between February 21, 2025 and August 28, 2025.
This legal action brings heightened scrutiny to Telix’s disclosures and may influence how investors assess the company’s transparency and governance practices going forward.
We'll explore...